- Conditions
- Contraception, Pain
- Interventions
- Insertion of nitroglycerin ointment, Insertion of placebo ointment
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 9,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Epinephrine HFA-MDI (E004), Placebo-HFA
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Cypress, California • Medford, Oregon • Portland, Oregon + 3 more
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1151
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
- Conditions
- Chronic Heart Failure
- Interventions
- HeartWare Ventricular Assist Device
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • San Diego, California • San Francisco, California + 25 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 6 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Non-Constipation Irritable Bowel Syndrome
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 86
- States / cities
- Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more
- Conditions
- Healthy
- Interventions
- Placebo supplement, Citicoline and Omega-3 supplement, Omega-3 supplement
- Dietary Supplement
- Lead sponsor
- Kyowa Hakko Bio Co., Ltd.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Health Behaviors, Obesity, Substance Abuse, Anxiety, Depression
- Interventions
- Implementation of the MOHR assessment in primary care workflow
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chapel Hill, North Carolina • Portland, Oregon + 5 more
- Conditions
- Molluscum Contagiosum
- Interventions
- SB206 12%, Placebo
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
- Conditions
- Small-Cell Lung Cancer, Neuroendocrine Carcinoma
- Interventions
- Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
- Biological
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Tobacco Smoking
- Interventions
- Yoga, Education
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma
- Interventions
- NXP900
- Drug
- Lead sponsor
- Nuvectis Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
- Interventions
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
- Drug · Radiation
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 25 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- INCB059872, all-trans retinoic acid (ATRA), azacitidine, nivolumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Alzheimer's Disease
- Interventions
- LY450139 dihydrate, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Bortezomib + Rituximab, Rituximab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 41
- States / cities
- Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more
- Conditions
- Major Depressive Disorder
- Interventions
- OPC-34712, Placebo, ADT
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 46
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 34 more
- Conditions
- Insomnia Disorder
- Interventions
- lemborexant, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Rogers, Arkansas • Beverly Hills, California + 35 more
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- etaracizumab, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
- Conditions
- Hydrocephalus, Normal Pressure Hydrocephalus
- Interventions
- Codman VPV System
- Device
- Lead sponsor
- Codman & Shurtleff
- Industry
- Eligibility
- Not listed
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Orlando, Florida • Boston, Massachusetts + 5 more
- Conditions
- Parkinson Disease, Huntington Disease
- Interventions
- No Intervention - Observational Study
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis
- Interventions
- BIIB033 (opicinumab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 51
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
- Conditions
- Atopic Dermatitis (Eczema)
- Interventions
- ARQ-151 cream 0.05%
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 3 Months to 2 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more